Login / Signup

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer.

Preti Beatrice Tabitha BassierMichael S SanataniDaniel A BreadnerSuganija LakkunarajahCarolyn ScottCaroline Esmonde-WhiteEric McArthurGeorge RodriguesMitali ChaudharyAdam MutsaersRobin SachdevaMark D Vincent
Published in: Current oncology (Toronto, Ont.) (2023)
The 2017 PACIFIC trial heralded the incorporation of routine adjuvant durvalumab following curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However, carefully selected clinical trial populations can differ significantly from real-world populations, which can have implications on treatment toxicities and outcomes, making it difficult to accurately counsel patients. Consequently, we performed a real-world, retrospective analysis of outcomes and toxicities in 118 patients with stage III NSCLC treated with durvalumab after platinum-based chemoradiotherapy. The data were collected from patients who underwent treatment at a single, tertiary-level Canadian cancer centre from May 2018 to October 2020. The variables collected included patient demographics, treatment specifics, progression-free survival, overall survival, and immune-related adverse events (IRAE) from durvalumab. Descriptive statistics were used for toxicity analysis, and progression-free survival and overall survival estimates were calculated using the Kaplan-Meier method. The statistical analyses indicated a 64.4% ( n = 76) toxicity rate, with a 21% ( n = 25) toxicity rate of grade 3+ IRAEs. The most common documented IRAEs were pneumonitis ( n = 44; 40%), followed by rash ( n = 20; 18%) and thyroid dysfunction ( n = 17; 15%). FEV1 and DLCO were not found to be associated predictors of pneumonitis toxicity. The median PFS and OS were estimated to be >1.7 years and >2.7 years, respectively.
Keyphrases